Strengths and weaknesses of pneumococcal conjugate vaccines.

Szczegóły
Abstrakt

Tytuł:: Strengths and weaknesses of pneumococcal conjugate vaccines.
Autorzy:: Micoli F; GSK Vaccines Institute for Global Health, Siena, Italy. .
Romano MR; GSK Vaccines, Siena, Italy.
Carboni F; GSK Vaccines, Siena, Italy.
Adamo R; GSK Vaccines, Siena, Italy.
Berti F; GSK Vaccines, Siena, Italy.
Źródło:: Glycoconjugate journal [Glycoconj J] 2023 Apr; Vol. 40 (2), pp. 135-148. Date of Electronic Publication: 2023 Jan 18.
Typ publikacji:: Journal Article; Review; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Publication: <2008->: Norwell, MA : Springer
Original Publication: [Lund : The Journal, c1984-
MeSH Terms:: Pneumococcal Vaccines*/therapeutic use
Pneumococcal Infections*/prevention & control
Pneumococcal Infections*/epidemiology
Humans ; Streptococcus pneumoniae ; Vaccination ; Vaccines, Conjugate/therapeutic use ; Antibodies, Bacterial
References:: Cell. 2004 May 28;117(5):677-87. (PMID: 15163414)
Clin Microbiol Infect. 2009 Apr;15 Suppl 3:16-20. (PMID: 19366365)
Nat Rev Immunol. 2006 Nov;6(11):849-58. (PMID: 17024229)
Clin Infect Dis. 2018 Jun 18;67(1):42-49. (PMID: 29324986)
J Biol Chem. 2011 Oct 14;286(41):35813-35822. (PMID: 21859716)
Heliyon. 2016 Nov 29;2(11):e00198. (PMID: 27957553)
Vaccine. 2017 Mar 1;35(9):1293-1298. (PMID: 28161425)
Clin Infect Dis. 2021 Oct 5;73(7):e1489-e1497. (PMID: 32716500)
Infect Immun. 2001 Feb;69(2):787-93. (PMID: 11159969)
Immunobiology. 2013 Mar;218(3):368-72. (PMID: 22704520)
Expert Rev Vaccines. 2017 Dec;16(12):1181-1190. (PMID: 29130395)
PLoS One. 2013 Sep 12;8(9):e72588. (PMID: 24069152)
Vaccine. 2022 Jul 29;40(31):4190-4198. (PMID: 35690500)
Clin Infect Dis. 2019 May 30;68(12):2135-2143. (PMID: 30357326)
PLoS Pathog. 2017 Jan 30;13(1):e1006137. (PMID: 28135322)
Clin Microbiol Rev. 2015 Jul;28(3):871-99. (PMID: 26085553)
Expert Rev Vaccines. 2011 Mar;10(3):307-22. (PMID: 21434799)
Lancet Infect Dis. 2004 Mar;4(3):144-54. (PMID: 14998500)
ACS Cent Sci. 2018 Mar 28;4(3):357-361. (PMID: 29632881)
Infect Immun. 1982 Jul;37(1):89-103. (PMID: 7107011)
J Infect Dis. 2001 Sep 15;184(6):789-93. (PMID: 11517443)
mBio. 2020 May 19;11(3):. (PMID: 32430472)
Nat Rev Microbiol. 2008 Apr;6(4):288-301. (PMID: 18340341)
Hum Vaccin. 2011 Oct;7(10):1012-8. (PMID: 21941097)
Clin Vaccine Immunol. 2015 Dec 16;23(2):162-7. (PMID: 26677201)
Carbohydr Res. 2003 Nov 14;338(23):2531-8. (PMID: 14670714)
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):12896-12901. (PMID: 30559195)
Clin Infect Dis. 2022 Aug 31;75(3):390-398. (PMID: 34940806)
Vaccine. 2021 Sep 7;39(38):5428-5435. (PMID: 34315611)
Chem Sci. 2020 Jun 26;11(28):7401-7407. (PMID: 34123020)
mBio. 2016 Jun 07;7(3):. (PMID: 27273824)
N Engl J Med. 2015 Mar 19;372(12):1114-25. (PMID: 25785969)
Proc Natl Acad Sci U S A. 2018 Dec 26;115(52):13353-13358. (PMID: 30530654)
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13564-9. (PMID: 23898212)
Public Health Rep. 2016 Jan-Feb;131(1):11-6. (PMID: 26843664)
Vaccine. 2021 May 27;39(23):3197-3206. (PMID: 33965258)
PLoS Med. 2010 Oct 05;7(10):. (PMID: 20957191)
Vaccine. 2016 Mar 18;34(13):1540-1550. (PMID: 26899372)
ACS Chem Biol. 2021 Sep 17;16(9):1671-1679. (PMID: 34469105)
Russ J Bioorg Chem. 2021;47(1):1-25. (PMID: 33776393)
Curr Opin Immunol. 2020 Aug;65:42-49. (PMID: 32361591)
Cell Chem Biol. 2016 Nov 17;23(11):1407-1416. (PMID: 27818299)
J Am Chem Soc. 2017 Oct 18;139(41):14783-14791. (PMID: 28945368)
Pediatrics. 2006 Sep;118(3):865-73. (PMID: 16950975)
Drugs. 2022 Jun;82(9):989-999. (PMID: 35793027)
Vaccine. 2018 Nov 26;36(49):7479-7486. (PMID: 30385056)
Can J Infect Dis Med Microbiol. 2016;2016:5381871. (PMID: 27366170)
Clin Vaccine Immunol. 2012 Aug;19(8):1296-303. (PMID: 22739693)
J Infect Dis. 2008 Apr 1;197(7):1016-27. (PMID: 18419539)
Front Mol Biosci. 2022 Aug 08;9:961532. (PMID: 36003080)
Expert Rev Vaccines. 2010 Mar;9(3):229-36. (PMID: 20218848)
Vaccine. 2011 Nov 15;29(49):9127-31. (PMID: 21983361)
Elife. 2018 Dec 28;7:. (PMID: 30592459)
Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1143-51. (PMID: 25699685)
BMC Infect Dis. 2010 Feb 10;10:22. (PMID: 20146815)
Annu Rev Immunol. 1995;13:655-92. (PMID: 7612238)
Microbiol Spectr. 2019 Mar;7(2):. (PMID: 30977464)
J Immunol. 2002 Dec 1;169(11):6149-53. (PMID: 12444118)
Hum Vaccin Immunother. 2019;15(3):530-539. (PMID: 30648919)
Expert Rev Vaccines. 2020 Jan;19(1):57-70. (PMID: 31903805)
Lancet Infect Dis. 2016 Jun;16(6):703-711. (PMID: 26897105)
MMWR Morb Mortal Wkly Rep. 2019 Nov 22;68(46):1069-1075. (PMID: 31751323)
Hum Vaccin Immunother. 2016;12(2):383-92. (PMID: 26535755)
Vaccine. 2021 Dec 17;39(51):7494-7502. (PMID: 34839993)
Clin Microbiol Infect. 2010 May;16(5):411-8. (PMID: 20132250)
Lancet Infect Dis. 2015 Mar;15(3):301-9. (PMID: 25656600)
J Biol Chem. 2010 Jul 30;285(31):24217-27. (PMID: 20507989)
Curr Opin Microbiol. 2012 Apr;15(2):194-203. (PMID: 22280885)
Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):11063-11068. (PMID: 28973947)
BMC Infect Dis. 2022 Mar 26;22(1):294. (PMID: 35346092)
Genes (Basel). 2019 Oct 25;10(11):. (PMID: 31731573)
Carbohydr Res. 2015 Apr 10;406:27-33. (PMID: 25658063)
Lancet Infect Dis. 2011 Oct;11(10):760-8. (PMID: 21621466)
Pulm Pharmacol Ther. 2015 Jun;32:124-9. (PMID: 24607597)
Semin Immunol. 2020 Aug;50:101433. (PMID: 33309166)
Nat Microbiol. 2020 Mar;5(3):473-485. (PMID: 32015499)
Sci Transl Med. 2017 Mar 8;9(380):. (PMID: 28275152)
J Immunol. 2013 Sep 15;191(6):3254-63. (PMID: 23926322)
Vaccines (Basel). 2020 Mar 17;8(1):. (PMID: 32192117)
Medicine (Baltimore). 2016 Sep;95(37):e4854. (PMID: 27631247)
Lancet Child Adolesc Health. 2018 Aug;2(8):561-568. (PMID: 30119715)
MMWR Morb Mortal Wkly Rep. 2005 Sep 16;54(36):893-7. (PMID: 16163262)
PLoS Pathog. 2007 Mar;3(3):e32. (PMID: 17367207)
Eur J Immunol. 2005 Feb;35(2):352-6. (PMID: 15682450)
N Engl J Med. 2014 Nov 13;371(20):1889-99. (PMID: 25386897)
J Clin Microbiol. 1995 Oct;33(10):2759-62. (PMID: 8567920)
Sci Rep. 2016 Apr 22;6:24931. (PMID: 27103188)
Pediatr Infect Dis J. 2017 Dec;36(12):e334-e340. (PMID: 28650416)
Contributed Indexing:: Keywords: Bacterial infection; Conjugate; Polysaccharide; Streptococcus pneumoniae; Vaccine
Substance Nomenclature:: 0 (Pneumococcal Vaccines)
0 (Vaccines, Conjugate)
0 (Antibodies, Bacterial)
Entry Date(s):: Date Created: 20230118 Date Completed: 20230322 Latest Revision: 20230411
Update Code:: 20240104
PubMed Central ID:: PMC10027807
DOI:: 10.1007/s10719-023-10100-3
PMID:: 36652051
: Czasopismo naukowe

Full Text Finder

Multivalent vaccines addressing an increasing number of Streptococcus pneumoniae types (7-, 10-, 13-, 15-, 20-valent) have been licensed over the last 22 years. The use of polysaccharide-protein conjugate vaccines has been pivotal in reducing the incidence of invasive pneumococcal disease despite the emergence of non-vaccine serotypes. Notwithstanding its undoubtable success, some weaknesses have called for continuous improvement of pneumococcal vaccination. For instance, despite their inclusion in pneumococcal conjugate vaccines, there are challenges associated with some serotypes. In particular, Streptococcus pneumoniae type 3 remains a major cause of invasive pneumococcal disease in several countries.Here a deep revision of the strengths and weaknesses of the licensed pneumococcal conjugate vaccines and other vaccine candidates currently in clinical development is reported.
(© 2023. The Author(s).)

Informacja